New MS drug shows promise in Long-Term trial
Disease control
Ongoing
This study looks at the long-term safety and effectiveness of ublituximab, a drug for relapsing multiple sclerosis (RMS). About 1,100 people who completed earlier studies will continue treatment. The main goal is to see how well the drug reduces relapse rates over time.
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:25 UTC